Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Multiple independent case reports have identified somatic rearrangements of the breakpoint cluster region gene (BCR) in acute myeloid leukemia (AML), most commonly as BCR::ABL1 fusions arising via t(9;22)(q34;q11.2). Five unrelated AML patients have been described with BCR–ABL rearrangements or variant fusions including BCR–JAK2, each confirmed by cytogenetics and molecular assays ([PMID:10049047]; [PMID:7950925]; [PMID:22549126]; [PMID:36307214]; [PMID:8330271]). These cases underscore the oncogenic role of BCR fusion proteins in driving myeloid transformation, although no familial segregation has been observed.
BCR encodes a dual-function protein with a Rho GTPase-activating (GAP) domain and a serine/threonine kinase domain. Mutational analyses of the GAP domain have delineated critical residues for Rac1 binding and GTPase activation, and studies of BCR–ABL serine/threonine kinase inhibition implicate dysregulated phosphorylation in leukemogenesis ([PMID:8021274]). Despite these insights, functional modeling in AML-specific systems remains limited.
Key take‐home: Somatic BCR fusions comprise a rare but clinically actionable subset of AML, warranting inclusion in targeted diagnostic panels.
Gene–Disease AssociationLimited5 AML probands with somatic BCR rearrangements across independent case reports; no familial segregation; limited functional correlation Genetic EvidenceLimitedSingle‐case reports of BCR-ABL and BCR-JAK2 fusions in AML: 1 proband each in five studies ([PMID:10049047], [PMID:7950925], [PMID:22549126], [PMID:36307214], [PMID:8330271]) Functional EvidenceLimitedMolecular studies of BCR GAP and kinase domains suggest potential oncogenic functions but lack direct AML model data ([PMID:8021274]) |